Skip to main content
Erschienen in: Journal of Clinical Immunology 1/2024

01.01.2024 | Original Article

Filaggrin-Associated Atopic Skin, Eye, Airways, and Gut Disease, Modifying the Presentation of X-Linked Reticular Pigmentary Disorder (XLPDR)

verfasst von: Margaret W. Y. Li, Leslie Burnett, Pei Dai, Danielle T. Avery, Tahereh Noori, Ilia Voskoboinik, Parth R. Shah, Artiene Tatian, Stuart G. Tangye, Paul E. Gray, Cindy S. Ma

Erschienen in: Journal of Clinical Immunology | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

X-linked reticular pigmentary disorder (XLPDR) is a rare condition characterized by skin hyperpigmentation, ectodermal features, multiorgan inflammation, and recurrent infections. All probands identified to date share the same intronic hemizygous POLA1 hypomorphic variant (NM_001330360.2(POLA1):c.1393-354A > G) on the X chromosome. Previous studies have supported excessive type 1 interferon (IFN) inflammation and natural killer (NK) cell dysfunction in disease pathogenesis. Common null polymorphisms in filaggrin (FLG) gene underlie ichthyosis vulgaris and atopic predisposition.

Case

A 9-year-old boy born to non-consanguineous parents developed eczema with reticular skin hyperpigmentation in early infancy. He suffered recurrent chest infections with chronic cough, clubbing, and asthma, moderate allergic rhinoconjunctivitis with keratitis, multiple food allergies, and vomiting with growth failure. Imaging demonstrated bronchiectasis, while gastroscopy identified chronic eosinophilic gastroduodenitis. Interestingly, growth failure and bronchiectasis improved over time without specific treatment.

Methods

Whole-genome sequencing (WGS) using Illumina short-read sequencing was followed by both manual and orthogonal automated bioinformatic analyses for single-nucleotide variants, small insertions/deletions (indels), and larger copy number variations. NK cell cytotoxic function was assessed using 51Cr release and degranulation assays. The presence of an interferon signature was investigated using a panel of six interferon-stimulated genes (ISGs) by QPCR.

Results

WGS identified a de novo hemizygous intronic variant in POLA1 (NM_001330360.2(POLA1):c.1393-354A > G) giving a diagnosis of XLPDR, as well as a heterozygous nonsense FLG variant (NM_002016.2(FLG):c.441del, NP_0020.1:p.(Arg151Glyfs*43)). Compared to healthy controls, the IFN signature was elevated although the degree moderated over time with the improvement in his chest disease. NK cell functional studies showed normal cytotoxicity and degranulation.

Conclusion

This patient had multiple atopic manifestations affecting eye, skin, chest, and gut, complicating the presentation of XLPDR. This highlights that common FLG polymorphisms should always be considered when assessing genotype–phenotype correlations of other genetic variation in patients with atopic symptoms. Additionally, while the patient exhibited an enhanced IFN signature, he does not have an NK cell defect, suggesting this may not be a constant feature of XLPDR.
Literatur
1.
Zurück zum Zitat Partington MW, Marriott PJ, Prentice RS, Cavaglia A, Simpson NE. Familial cutaneous amyloidosis with systemic manifestations in males. Am J Med Genet. 1981;10(1):65–75.PubMedCrossRef Partington MW, Marriott PJ, Prentice RS, Cavaglia A, Simpson NE. Familial cutaneous amyloidosis with systemic manifestations in males. Am J Med Genet. 1981;10(1):65–75.PubMedCrossRef
2.
Zurück zum Zitat Adès LC, Rogers M, Sillence DO. An X-linked reticulate pigmentary disorder with systemic manifestations: report of a second family. Pediatr Dermatol. 1993;10(4):344–51.PubMedCrossRef Adès LC, Rogers M, Sillence DO. An X-linked reticulate pigmentary disorder with systemic manifestations: report of a second family. Pediatr Dermatol. 1993;10(4):344–51.PubMedCrossRef
3.
Zurück zum Zitat Anderson RC, Zinn AR, Kim J, Carder KR. X-linked reticulate pigmentary disorder with systemic manifestations: report of a third family and literature review. Pediatr Dermatol. 2005;22(2):122–6.PubMedCrossRef Anderson RC, Zinn AR, Kim J, Carder KR. X-linked reticulate pigmentary disorder with systemic manifestations: report of a third family and literature review. Pediatr Dermatol. 2005;22(2):122–6.PubMedCrossRef
4.
Zurück zum Zitat Fernandez-Guarino M, Torrelo A, Fernandez-Lorente M, Fraile G, García-Sagredo JM, Jaén P. X-linked reticulate pigmentary disorder: report of a new family. Eur J Dermatol. 2008;18(1):102–3.PubMed Fernandez-Guarino M, Torrelo A, Fernandez-Lorente M, Fraile G, García-Sagredo JM, Jaén P. X-linked reticulate pigmentary disorder: report of a new family. Eur J Dermatol. 2008;18(1):102–3.PubMed
5.
Zurück zum Zitat Mégarbané H, Boehm N, Chouery E, Bernard R, Salem N, Halaby E, et al. X-linked reticulate pigmentary layer. Report of a new patient and demonstration of a skewed X-inactivation. Genet Couns. 2005;16(1):85–9.PubMed Mégarbané H, Boehm N, Chouery E, Bernard R, Salem N, Halaby E, et al. X-linked reticulate pigmentary layer. Report of a new patient and demonstration of a skewed X-inactivation. Genet Couns. 2005;16(1):85–9.PubMed
6.
Zurück zum Zitat Pezzani L, Brena M, Callea M, Colombi M, Tadini G. X-linked reticulate pigmentary disorder with systemic manifestations: a new family and review of the literature. Am J Med Genet A. 2013;161a(6):1414–20.PubMedCrossRef Pezzani L, Brena M, Callea M, Colombi M, Tadini G. X-linked reticulate pigmentary disorder with systemic manifestations: a new family and review of the literature. Am J Med Genet A. 2013;161a(6):1414–20.PubMedCrossRef
7.
Zurück zum Zitat Zhao YK, Fan LH, Lu JF, Luo ZY, Lin ZM, Wang HJ, et al. X-linked reticulate pigmentary disorder in a 4-year-old boy. Postepy Dermatol Alergol. 2022;39(2):410–2.PubMedPubMedCentralCrossRef Zhao YK, Fan LH, Lu JF, Luo ZY, Lin ZM, Wang HJ, et al. X-linked reticulate pigmentary disorder in a 4-year-old boy. Postepy Dermatol Alergol. 2022;39(2):410–2.PubMedPubMedCentralCrossRef
8.
Zurück zum Zitat Légeret C, Meyer BJ, Rovina A, Deigendesch N, Berger CT, Daikeler T, et al. JAK inhibition in a patient with X-linked reticulate pigmentary disorder. J Clin Immunol. 2021;41(1):212–6.PubMedCrossRef Légeret C, Meyer BJ, Rovina A, Deigendesch N, Berger CT, Daikeler T, et al. JAK inhibition in a patient with X-linked reticulate pigmentary disorder. J Clin Immunol. 2021;41(1):212–6.PubMedCrossRef
9.
Zurück zum Zitat Xu ZLZ. Image gallery: cutaneous findings in an adult with X-linked reticulate pigmentary disorder. Br J Dermatol. 2019;180(2):37.CrossRef Xu ZLZ. Image gallery: cutaneous findings in an adult with X-linked reticulate pigmentary disorder. Br J Dermatol. 2019;180(2):37.CrossRef
10.
Zurück zum Zitat Fraile G, Norman F, Reguero ME, Defargues V, Redondo C. Cryptogenic multifocal ulcerous stenosing enteritis (CMUSE) in a man with a diagnosis of X-linked reticulate pigmentary disorder (PDR). Scand J Gastroenterol. 2008;43(4):506–10.PubMedCrossRef Fraile G, Norman F, Reguero ME, Defargues V, Redondo C. Cryptogenic multifocal ulcerous stenosing enteritis (CMUSE) in a man with a diagnosis of X-linked reticulate pigmentary disorder (PDR). Scand J Gastroenterol. 2008;43(4):506–10.PubMedCrossRef
11.
Zurück zum Zitat Motaparthi K, Hall B. Reticulate hyperpigmentation in a man with hypohidrosis and sinopulmonary infections. JAMA Dermatol. 2017;153(8):817–8.PubMedCrossRef Motaparthi K, Hall B. Reticulate hyperpigmentation in a man with hypohidrosis and sinopulmonary infections. JAMA Dermatol. 2017;153(8):817–8.PubMedCrossRef
12.
Zurück zum Zitat Starokadomskyy P, Sifuentes-Dominguez L, Gemelli T, Zinn AR, Dossi MT, Mellado C, et al. Evolution of the skin manifestations of X-linked pigmentary reticulate disorder. Br J Dermatol. 2017;177(5):e200–1.PubMedPubMedCentralCrossRef Starokadomskyy P, Sifuentes-Dominguez L, Gemelli T, Zinn AR, Dossi MT, Mellado C, et al. Evolution of the skin manifestations of X-linked pigmentary reticulate disorder. Br J Dermatol. 2017;177(5):e200–1.PubMedPubMedCentralCrossRef
13.
Zurück zum Zitat Duman N, Ersoy-Evans S, Gököz Ö. Reticulate pigmentation with systemic manifestations in a child. Pediatr Dermatol. 2015;32(6):871–2.PubMedCrossRef Duman N, Ersoy-Evans S, Gököz Ö. Reticulate pigmentation with systemic manifestations in a child. Pediatr Dermatol. 2015;32(6):871–2.PubMedCrossRef
14.
Zurück zum Zitat Starokadomskyy P, Escala Perez-Reyes A, Burstein E. Immune dysfunction in Mendelian disorders of POLA1 deficiency. J Clin Immunol. 2021;41(2):285–93.PubMedPubMedCentralCrossRef Starokadomskyy P, Escala Perez-Reyes A, Burstein E. Immune dysfunction in Mendelian disorders of POLA1 deficiency. J Clin Immunol. 2021;41(2):285–93.PubMedPubMedCentralCrossRef
15.
Zurück zum Zitat Gedeon AK, Mulley JC, Kozman H, Donnelly A, Partington MW. Localisation of the gene for X-linked reticulate pigmentary disorder with systemic manifestations (PDR), previously known as X-linked cutaneous amyloidosis. Am J Med Genet. 1994;52(1):75–8.PubMedCrossRef Gedeon AK, Mulley JC, Kozman H, Donnelly A, Partington MW. Localisation of the gene for X-linked reticulate pigmentary disorder with systemic manifestations (PDR), previously known as X-linked cutaneous amyloidosis. Am J Med Genet. 1994;52(1):75–8.PubMedCrossRef
16.
Zurück zum Zitat Jaeckle Santos LJ, Xing C, Barnes RB, Ades LC, Megarbane A, Vidal C, et al. Refined mapping of X-linked reticulate pigmentary disorder and sequencing of candidate genes. Hum Genet. 2008;123(5):469–76.PubMedCrossRef Jaeckle Santos LJ, Xing C, Barnes RB, Ades LC, Megarbane A, Vidal C, et al. Refined mapping of X-linked reticulate pigmentary disorder and sequencing of candidate genes. Hum Genet. 2008;123(5):469–76.PubMedCrossRef
17.
Zurück zum Zitat Starokadomskyy P, Gemelli T, Rios JJ, Xing C, Wang RC, Li H, et al. DNA polymerase-α regulates the activation of type I interferons through cytosolic RNA:DNA synthesis. Nat Immunol. 2016;17(5):495–504.PubMedPubMedCentralCrossRef Starokadomskyy P, Gemelli T, Rios JJ, Xing C, Wang RC, Li H, et al. DNA polymerase-α regulates the activation of type I interferons through cytosolic RNA:DNA synthesis. Nat Immunol. 2016;17(5):495–504.PubMedPubMedCentralCrossRef
18.
Zurück zum Zitat Van Esch H, Colnaghi R, Freson K, Starokadomskyy P, Zankl A, Backx L, et al. Defective DNA polymerase α-primase leads to X-linked intellectual disability associated with severe growth retardation, microcephaly, and hypogonadism. Am J Hum Genet. 2019;104(5):957–67.PubMedPubMedCentralCrossRef Van Esch H, Colnaghi R, Freson K, Starokadomskyy P, Zankl A, Backx L, et al. Defective DNA polymerase α-primase leads to X-linked intellectual disability associated with severe growth retardation, microcephaly, and hypogonadism. Am J Hum Genet. 2019;104(5):957–67.PubMedPubMedCentralCrossRef
19.
Zurück zum Zitat Kim BS, Seo SH, Jung HD, Kwon KS, Kim MB. X-Linked reticulate pigmentary disorder in a female patient. Int J Dermatol. 2010;49(4):421–5.PubMedCrossRef Kim BS, Seo SH, Jung HD, Kwon KS, Kim MB. X-Linked reticulate pigmentary disorder in a female patient. Int J Dermatol. 2010;49(4):421–5.PubMedCrossRef
20.
Zurück zum Zitat Jaffar H, Shakir Z, Kumar G, Ali IF. Ichthyosis vulgaris: an updated review. Skin Health Dis. 2023;3(1):e187.PubMedCrossRef Jaffar H, Shakir Z, Kumar G, Ali IF. Ichthyosis vulgaris: an updated review. Skin Health Dis. 2023;3(1):e187.PubMedCrossRef
21.
Zurück zum Zitat Čepelak I, Dodig S, Pavić I. Filaggrin and atopic march. Biochem Med (Zagreb). 2019;29(2):020501.PubMedCrossRef Čepelak I, Dodig S, Pavić I. Filaggrin and atopic march. Biochem Med (Zagreb). 2019;29(2):020501.PubMedCrossRef
23.
Zurück zum Zitat Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006;38(4):441–6.PubMedCrossRef Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006;38(4):441–6.PubMedCrossRef
24.
Zurück zum Zitat van den Oord RA, Sheikh A. Filaggrin gene defects and risk of developing allergic sensitisation and allergic disorders: systematic review and meta-analysis. BMJ. 2009;339:b2433.PubMedPubMedCentralCrossRef van den Oord RA, Sheikh A. Filaggrin gene defects and risk of developing allergic sensitisation and allergic disorders: systematic review and meta-analysis. BMJ. 2009;339:b2433.PubMedPubMedCentralCrossRef
25.
Zurück zum Zitat Heimall J, Spergel JM. Filaggrin mutations and atopy: consequences for future therapeutics. Expert Rev Clin Immunol. 2012;8(2):189–97.PubMedCrossRef Heimall J, Spergel JM. Filaggrin mutations and atopy: consequences for future therapeutics. Expert Rev Clin Immunol. 2012;8(2):189–97.PubMedCrossRef
26.
Zurück zum Zitat Kottyan LC, Davis BP, Sherrill JD, Liu K, Rochman M, Kaufman K, et al. Genome-wide association analysis of eosinophilic esophagitis provides insight into the tissue specificity of this allergic disease. Nat Genet. 2014;46(8):895–900.PubMedPubMedCentralCrossRef Kottyan LC, Davis BP, Sherrill JD, Liu K, Rochman M, Kaufman K, et al. Genome-wide association analysis of eosinophilic esophagitis provides insight into the tissue specificity of this allergic disease. Nat Genet. 2014;46(8):895–900.PubMedPubMedCentralCrossRef
27.
Zurück zum Zitat Blanchard C, Stucke EM, Burwinkel K, Caldwell JM, Collins MH, Ahrens A, et al. Coordinate interaction between IL-13 and epithelial differentiation cluster genes in eosinophilic esophagitis. J Immunol. 2010;184(7):4033–41.PubMedCrossRef Blanchard C, Stucke EM, Burwinkel K, Caldwell JM, Collins MH, Ahrens A, et al. Coordinate interaction between IL-13 and epithelial differentiation cluster genes in eosinophilic esophagitis. J Immunol. 2010;184(7):4033–41.PubMedCrossRef
28.
Zurück zum Zitat Weidinger S, O’Sullivan M, Illig T, Baurecht H, Depner M, Rodriguez E, et al. Filaggrin mutations, atopic eczema, hay fever, and asthma in children. J Allergy Clin Immunol. 2008;121(5):1203-9.e1.PubMedCrossRef Weidinger S, O’Sullivan M, Illig T, Baurecht H, Depner M, Rodriguez E, et al. Filaggrin mutations, atopic eczema, hay fever, and asthma in children. J Allergy Clin Immunol. 2008;121(5):1203-9.e1.PubMedCrossRef
29.
Zurück zum Zitat Moosbrugger-Martinz V, Leprince C, Méchin MC, Simon M, Blunder S, Gruber R, et al. Revisiting the roles of filaggrin in atopic dermatitis. Int J Mol Sci. 2022;23(10):5318. Moosbrugger-Martinz V, Leprince C, Méchin MC, Simon M, Blunder S, Gruber R, et al. Revisiting the roles of filaggrin in atopic dermatitis. Int J Mol Sci. 2022;23(10):5318.
30.
Zurück zum Zitat Drislane C, Irvine AD. The role of filaggrin in atopic dermatitis and allergic disease. Ann Allergy Asthma Immunol. 2020;124(1):36–43.PubMedCrossRef Drislane C, Irvine AD. The role of filaggrin in atopic dermatitis and allergic disease. Ann Allergy Asthma Immunol. 2020;124(1):36–43.PubMedCrossRef
31.
Zurück zum Zitat Clark MM, Hildreth A, Batalov S, Ding Y, Chowdhury S, Watkins K, et al. Diagnosis of genetic diseases in seriously ill children by rapid whole-genome sequencing and automated phenotyping and interpretation. Sci Transl Med. 2019;11(489):eaat6177.PubMedPubMedCentralCrossRef Clark MM, Hildreth A, Batalov S, Ding Y, Chowdhury S, Watkins K, et al. Diagnosis of genetic diseases in seriously ill children by rapid whole-genome sequencing and automated phenotyping and interpretation. Sci Transl Med. 2019;11(489):eaat6177.PubMedPubMedCentralCrossRef
32.
Zurück zum Zitat Partington MW, Prentice RS. X-linked cutaneous amyloidosis: further clinical and pathological observations. Am J Med Genet. 1989;32(1):115–9.PubMedCrossRef Partington MW, Prentice RS. X-linked cutaneous amyloidosis: further clinical and pathological observations. Am J Med Genet. 1989;32(1):115–9.PubMedCrossRef
35.
Zurück zum Zitat Starokadomskyy P, Wilton KM, Krzewski K, Lopez A, Sifuentes-Dominguez L, Overlee B, et al. NK cell defects in X-linked pigmentary reticulate disorder. JCI Insight. 2019;4(21):e125688. Starokadomskyy P, Wilton KM, Krzewski K, Lopez A, Sifuentes-Dominguez L, Overlee B, et al. NK cell defects in X-linked pigmentary reticulate disorder. JCI Insight. 2019;4(21):e125688.
36.
Zurück zum Zitat Minoche AE, Lundie B, Peters GB, Ohnesorg T, Pinese M, Thomas DM, et al. ClinSV: clinical grade structural and copy number variant detection from whole genome sequencing data. Genome Med. 2021;13(1):32.PubMedPubMedCentralCrossRef Minoche AE, Lundie B, Peters GB, Ohnesorg T, Pinese M, Thomas DM, et al. ClinSV: clinical grade structural and copy number variant detection from whole genome sequencing data. Genome Med. 2021;13(1):32.PubMedPubMedCentralCrossRef
37.
38.
Zurück zum Zitat Paila U, Chapman BA, Kirchner R, Quinlan AR. GEMINI: integrative exploration of genetic variation and genome annotations. PLoS Comput Biol. 2013;9(7):e1003153.PubMedPubMedCentralCrossRef Paila U, Chapman BA, Kirchner R, Quinlan AR. GEMINI: integrative exploration of genetic variation and genome annotations. PLoS Comput Biol. 2013;9(7):e1003153.PubMedPubMedCentralCrossRef
39.
Zurück zum Zitat Gayevskiy V, Roscioli T, Dinger ME, Cowley MJ. Seave: a comprehensive web platform for storing and interrogating human genomic variation. Bioinformatics. 2019;35(1):122–5.PubMedCrossRef Gayevskiy V, Roscioli T, Dinger ME, Cowley MJ. Seave: a comprehensive web platform for storing and interrogating human genomic variation. Bioinformatics. 2019;35(1):122–5.PubMedCrossRef
40.
Zurück zum Zitat Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405–24.PubMedPubMedCentralCrossRef Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405–24.PubMedPubMedCentralCrossRef
41.
Zurück zum Zitat den Dunnen JT, Dalgleish R, Maglott DR, Hart RK, Greenblatt MS, McGowan-Jordan J, et al. HGVS recommendations for the description of sequence variants: 2016 update. Hum Mutat. 2016;37(6):564–9.CrossRef den Dunnen JT, Dalgleish R, Maglott DR, Hart RK, Greenblatt MS, McGowan-Jordan J, et al. HGVS recommendations for the description of sequence variants: 2016 update. Hum Mutat. 2016;37(6):564–9.CrossRef
42.
Zurück zum Zitat Wright CF, FitzPatrick DR, Ware JS, Rehm HL, Firth HV. Importance of adopting standardized MANE transcripts in clinical reporting. Genet Med. 2023;25(2):100331.PubMedCrossRef Wright CF, FitzPatrick DR, Ware JS, Rehm HL, Firth HV. Importance of adopting standardized MANE transcripts in clinical reporting. Genet Med. 2023;25(2):100331.PubMedCrossRef
43.
Zurück zum Zitat Yap JY, Moens L, Lin M-W, Kane A, Kelleher A, Toong C, et al. Intrinsic defects in B cell development and differentiation, T cell exhaustion and altered unconventional T cell generation characterize human adenosine deaminase type 2 deficiency. J Clin Immunol. 2021;41(8):1915–35.PubMedPubMedCentralCrossRef Yap JY, Moens L, Lin M-W, Kane A, Kelleher A, Toong C, et al. Intrinsic defects in B cell development and differentiation, T cell exhaustion and altered unconventional T cell generation characterize human adenosine deaminase type 2 deficiency. J Clin Immunol. 2021;41(8):1915–35.PubMedPubMedCentralCrossRef
44.
Zurück zum Zitat Gray PE, Shadur B, Russell S, Mitchell R, Buckley M, Gallagher K, et al. Late-onset non-HLH presentations of growth arrest, inflammatory arachnoiditis, and severe infectious mononucleosis, in siblings with hypomorphic defects in UNC13D. Front Immunol. 2017;8:944.PubMedPubMedCentralCrossRef Gray PE, Shadur B, Russell S, Mitchell R, Buckley M, Gallagher K, et al. Late-onset non-HLH presentations of growth arrest, inflammatory arachnoiditis, and severe infectious mononucleosis, in siblings with hypomorphic defects in UNC13D. Front Immunol. 2017;8:944.PubMedPubMedCentralCrossRef
Metadaten
Titel
Filaggrin-Associated Atopic Skin, Eye, Airways, and Gut Disease, Modifying the Presentation of X-Linked Reticular Pigmentary Disorder (XLPDR)
verfasst von
Margaret W. Y. Li
Leslie Burnett
Pei Dai
Danielle T. Avery
Tahereh Noori
Ilia Voskoboinik
Parth R. Shah
Artiene Tatian
Stuart G. Tangye
Paul E. Gray
Cindy S. Ma
Publikationsdatum
01.01.2024
Verlag
Springer US
Erschienen in
Journal of Clinical Immunology / Ausgabe 1/2024
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-023-01637-x

Weitere Artikel der Ausgabe 1/2024

Journal of Clinical Immunology 1/2024 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Hereditäres Angioödem: Tablette könnte Akuttherapie erleichtern

05.06.2024 Hereditäres Angioödem Nachrichten

Medikamente zur Bedarfstherapie bei hereditärem Angioödem sind bisher nur als Injektionen und Infusionen verfügbar. Der Arzneistoff Sebetralstat kann oral verabreicht werden und liefert vielversprechende Daten.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.